# Finafloxacin

**Cat. No.:** HY-13451

**CAS No.:** 209342-40-5

**Molecular Formula:** $C_{20}H_{19}FN_4O_4$

**Molecular Weight:** 398.39

**Target:** Bacterial; Antibiotic

**Pathway:** Anti-infection

**Storage:**

| | | |
|---|---|---|
| Powder | -20°C | 3 years |
| | 4°C | 2 years |
| In solvent | -80°C | 2 years |
| | -20°C | 1 year |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 6.4 mg/mL (16.06 mM; Need ultrasonic and warming)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 2.5101 mL | 12.5505 mL | 25.1010 mL |
| | 5 mM | 0.5020 mL | 2.5101 mL | 5.0202 mL |
| | 10 mM | 0.2510 mL | 1.2551 mL | 2.5101 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

Finafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments. Target: AntibacterialFinafloxacin is a pH-activated fluoroquinolone (belonging to a new 8-cyano subclass) to treat serious bacterial infections associated with an acidic environment, including urinary tract infections (UTIs) and Helicobacter pylori infections. Finafloxacin exhibits optimal efficacy in slightly acidic environments (pH 5.0-6.0), under which other fluoroquinolones lose activity. Finafloxacin is highly selective for bacterial type II topoisomerases, including DNA gyrase and DNA topoisomerase IV. [1]

**$IC_{50}$ & Target**

Quinolone

## CUSTOMER VALIDATION

- Microb Pathog. 2023 Apr 22;106122.

See more customer validations on www.MedChemExpress.com

## REFERENCES

[1]. McKeage K. Finafloxacin: first global approval. Drugs. 2015 Apr;75(6):687-93.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA